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Abstract 
Purpose: To investigate the preventive effect of resveratrol against renal pathological changes in a rat 
model of chronic kidney disease (CKD).  
Methods: CKD was induced by daily intragastric administration of adenine (200 mg/kg) for 1 month. 
The effect of 10, 15, and 20 mg/kg doses of resveratrol on the levels of parathyroid hormone, 
phosphorous, and fibroblast growth factor-23 (FGF-23) in rat urine samples after 2 months of adenine 
administration were analyzed using an auto-analyzer.  
Results: Resveratrol treatment significantly inhibited the adenine-mediated increase in serum 
parathyroid hormone, phosphorous and FGF-23 levels (p < 0.002). In rats treated with 10, 15 and 20 
mg/kg doses of resveratrol after adenine, urine protein/creatinine ratio was reduced to 5, 675.6 ± 
2453.7, 4, 789.8 ± 1,534.9, and 1, 965 ± 576.8 mg/g, respectively. In the untreated and normal control 
groups, the respective values were 7, 004 ± 1, 653.3 and 1, 627.5 ± 568.7 mg/g. Treatment with 
resveratrol after administration of adenine inhibited increases in creatinine, blood urea nitrogen, and uric 
acid levels in a dose-dependent manner (p < 0.002). Resveratrol treatment also inhibited adenine-
mediated increases in monocytes and inflammatory cells. Furthermore, resveratrol prevented renal 
tubule swelling and expansion induced by adenine administration. 
Conclusion: Resveratrol treatment prevent the renal pathological changes induced by adenine 
administration in a rat model of CKD by inhibiting FGF-23, parathyroid hormone, and phosphate. Thus, 
resveratrol may be of therapeutic importance for the treatment of CKD.  
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Chronic kidney disease (CKD) is associated with 
inflammation and hemodynamic changes that 
result in scarring of the renal tubules and 
interstitial spaces, and ultimately, the 
development of end-stage renal disease [1]. CKD 
is frequently diagnosed and currently represents 
the leading cause of death among patients with 
diabetes and hypertension [1].  
 
Studies have shown that a prolonged increase in 
the serum levels of proteinuria and fibroblast 
growth factor-23 (FGF-23) is the main cause of 
end-stage renal disease [2,3]. Production of 
FGF-23 by bone catalyzes the excretion of 
inorganic phosphate from the kidneys via the 
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urine [4]. FGF-23 also inhibits the generation of 
vitamin D and maintains the balance between 
calcium and inorganic phosphate [4]. High levels 
of inorganic phosphate, parathyroid hormone, 
and FGF-23 in the serum promote the 
development of CKD [5]. Another factor that 
contributes to the development of kidney and 
heart disease is the presence of high levels of 
protein in urine [6]. Increased proteinuria 
interferes with the normal functioning of renal 
tubules and its suppression may be of 
therapeutic significance with respect to restoring 
normal kidney function. Therefore, reducing high 
levels of proteinuria should be a target for 
improving renal tubule function, and ultimately, 
treatment of CKD [6]. 
 
Trans-3, 5, 4’-trihydroxystilbene, commonly 
known as resveratrol, is a polyphenolic 
compound found in grapes, mulberries, and 
peanuts. Resveratrol exhibits a wide range of 
biological activities such as anti-fungal, anti-
inflammatory, anti-mutagenic, and anti-cancer 
effects [7]. Resveratrol confers potent anti-
inflammatory effects by inhibiting cellular 
inflammatory processes [8], and also inhibits the 
functions of chondrocytes by targeting the 
expression of interleukin-1β and inhibiting the 
generation of reactive oxygen species [9]. 
Resveratrol treatment also inhibits the production 
of inducible nitric oxide synthase by human 
epithelial cells [10]. In addition, it prevents 
cartilage degradation in animal models of arthritis 
[11]. This study examined the utility of resveratrol 
for treating CKD by suppressing the expression 
of inorganic phosphate, parathyroid hormone, 




Chemicals and reagents 
 
The adenine and resveratrol used in this study 
were obtained from Sigma-Aldrich (St. Louis, 
MO, USA). 
 
Animal study protocols 
 
Twenty-five male Sprague-Dawley rats, each 
weighing about 200 g, were obtained from the 
Experimental Animal Center of Hebei Medical 
University [animal license: SCXK (Hebei 2015-2-
034)]. The animal studies were approved by 
department of nephrology, Heping Hospital 
affiliated  to Changzhi Medical College, 
Changzhi, Shanxi, China (Approval No: 
RXT52323). The rats were acclimatized to the 
laboratory conditions for 1 week before beginning 
the experiment, and were housed under a 12 
h/12 h light/dark cycle at a constant temperature 
of 25 ± 1 °C and humidity in the range of 50 ‒ 60 
%. All of the animals had free access to food and 
water. The experimental protocols used were in 
accordance with the international suggestions for 
the Care and Use of Laboratory Animals (NIH 
publication no. 85-23, revised 1985) [12]. The 
animals were randomly assigned to five groups 
of five animals each. The rats in four of the 
groups (model group and three treatment 
groups) were administered adenine daily (200 
mg/kg intragastrically) for 1 month. The three 
treatment groups were given 10, 15, and 20 
mg/kg doses of resveratrol daily for 2 months, 
and the model group received normal saline.  
 
Resveratrol was delivered through the 
intragastric route, and rats in the normal group 
received an equal volume of normal saline alone 
during the treatment period. Completion of 
treatment was followed by animal sacrifice, with 
halothane used to extract the kidney and collect 
the blood samples. At 24 h before sacrifice, urine 
was collected from each rat for analysis 
according to a previously reported protocol [13]. 
 
Analysis of kidney damage 
 
The levels of creatinine and blood urea nitrogen 
(BUN) in the blood and urine samples were 
determined using an automatic biochemistry 
analyzer (Hitachi 7600-020/7170A; Hitachi High-
Technologies Corp., Tokyo, Japan). Briefly, the 
blood and urine samples collected from the rats 
were subjected to centrifugation for 15 min at 1, 
120 × g. The levels of creatinine, BUN, 
parathyroid hormone, phosphorous, and uric acid 
in the urine samples, as well as the 
protein/creatinine ratio, were analyzed using the 
biochemistry analyzer [13].  
 
Analysis of pathological changes in renal 
tubules 
 
The extracted kidneys were washed with 
phosphate-buffered saline (PBS) and fixed with 
buffered formalin (10 %), after which they were 
subjected to paraffin embedding, as previously 
reported [13]. The paraffin-embedded samples 
were cut into thin (2 μm) sections and boiled in 
xylene solution. The sections were stained with 
hematoxylin and eosin to analyze changes in 
renal tubule morphology under a magnification of 
400×. Three regions of each section were 
examined randomly.  
 
Analysis of serum fibroblast growth factor-23 
 
The levels of FGF-23 in rat serum samples were 
analyzed using an FGF-23 enzyme-linked 
immunosorbent assay (ELISA) kit (Immutopics, 
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San Clemente, CA, USA) according to the 
manufacturer’s protocol. Briefly, the serum 
samples were subjected to centrifugation for 10 
min at 1,500 rpm and subsequently stored at -20 
°C for ELISA analysis. The serum samples were 
subjected to culture for 24 h after being added to 
96-well microplates pre-coated with mouse 
monoclonal FGF-23 antibodies. After culture, the 
plates were washed and treated with horseradish 
peroxidase-conjugated polyclonal FGF-23 
secondary antibodies. Then the plates were 
washed again and treated with H2O2 and 
tetramethylbenzidine followed by measurement 




The data are presented as means ± SD for each 
rat group. Analysis of the statistical differences 
between both groups of rats was done using 
unpaired Student’s t-tests. Differences among all 
groups were analyzed by one-way analysis of 
variance with Bonferroni correction applied. All of 
the data were analyzed using SPSS software 
(ver. 12.0; SPSS, Inc., Chicago, IL, USA). P < 




Effects of resveratrol treatment on adenine-
mediated upregulation of FGF23, inorganic 
phosphate, and parathyroid hormone in rat 
serum 
 
Adenine administration markedly increased the 
levels of FGF-23, inorganic phosphate, and 
parathyroid hormone in rat serum compared to 
those of the control group (p < 0.005). However, 
treatment with resveratrol after adenine 
administration significantly reduced the increases 
in serum FGF-23, inorganic phosphate, and 
parathyroid hormone relative to the model control 
group (Figure 1). The serum levels of FGF-23 
and parathyroid hormone were very similar 
between the normal and resveratrol-treated (20 
mg/kg) rats. 
 
Effects of resveratrol treatment on adenine-
mediated increase in urine protein/creatinine 
ratio 
 
In rats administered adenine, the urine 
protein/creatinine ratio was markedly increased 
compared to that of the normal group. Treatment 
with resveratrol after adenine significantly 
attenuated this increase in the protein/creatinine 
ratio (p < 0.001). In the rats treated with 10, 15, 
and 20 mg/kg doses of resveratrol after adenine 
administration, the urine protein/creatinine ratio 
was reduced significantly, to 5, 675.6 ± 2, 453.7, 
4, 789.8 ± 1, 534.9 and 1, 965 ± 576.8 mg/g, 
respectively, compared to values in the model 
control group (7, 004 ± 1, 653.3). The urine 
protein/creatinine ratio of the normal control 
group was 1, 627.5 ± 568.7 mg/g (Figure 2). The 
increase in uric acid level caused by adenine 
administration was also significantly reduced by 
treatment with resveratrol in all three dose 
groups (p < 0.002). 
 
Resveratrol treatment lowered the adenine-
mediated increase in serum creatinine and 
BUN levels 
 
In rats administered adenine, the serum levels of 
creatinine and BUN were markedly increased 
compared to those of the normal group (p < 
0.002). Treatment with resveratrol after 
administration of adenine attenuated the 
increases in creatinine and BUN levels in a dose-




Figure 1: Effects of resveratrol on adenine-induced increases in fibroblast growth factor-23 (FGF-23), 
inorganic phosphate, and parathyroid hormone levels. Rats in the treatment groups were given 10, 
15, and 20 mg/kg doses of resveratrol after adenine administration, whereas the normal rats only 
received saline. The control group was given normal saline after adenine administration; *p < 0.05, **p 
< 0.01, #p < 0.05, and ##p < 0.01 compared to the model control group 
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Figure 2: Effects of resveratrol treatment on the 
adenine-mediated increase in the urine 
protein/creatinine ratio. Rats administered 
adenine were treated with 10, 15, and 20 mg/kg 
doses of resveratrol or normal saline (control). 
The urine of the rats was collected over a 24 h 
period to determine the levels of protein and 
creatinine; *p < 0.05 and **p < 0.01 compared to 
the untreated control group 
 
 
Figure 3: Effects of resveratrol treatment on 
levels of creatinine and blood urea nitrogen 
(BUN). Rats administered adenine were treated 
with 10, 15, and 20 mg/kg doses of resveratrol or 
normal saline (control). The serum levels of 
creatinine (µmol/L) and BUN (mmol/L) were 
analyzed; *p < 0.05, **p < 0.01, #p < 0.05 and 
##p < 0.01 compared to the untreated control 
group 
 
Resveratrol treatment prevents adenine-
induced pathological changes in rat kidney 
 
Administration of adenine caused changes in the 
renal tubules in the kidneys of the rats. 
Examination of the renal tubules of rats 
administered adenine revealed marked swelling 
and expansion (p < 0.005). The tubules in the 
adenine groups had higher levels of 
dihydroxyadenine than normal control rats, and 
the renal tissues also had marked increases in 
monocytes and inflammatory cells (p < 0.002; 
Figure 4). Resveratrol treatment inhibited the 
adenine-mediated increase in monocytes and 
inflammatory cells and prevented renal tubule 




Acute kidney injury is encountered frequently 
during clinical practice and affects the survival of 
patients. Injury to the renal tubules leads to acute 
renal failure in more than 80 % of patients 
[14,15]. This study demonstrated curative effects 
of resveratrol on the renal pathological changes 
occurring in a rat model of CKD, in which the 
animals were administered adenine 
intragastrically. 
 
Levels of phosphorus and calcium in the kidneys 
are regulated and maintained by various 
hormones such as parathyroid hormone, 
calcitriol, and FGF-23 [16]. Upregulation of 
phosphorus, FGF-23, and parathyroid hormone 
is associated with worsening kidney disease and 
a higher likelihood of death [17,18]. This study 
demonstrated a marked decrease in adenine-
induced increases in serum phosphorus, FGF-
23, and parathyroid hormone levels in rats, 
suggesting the preventative effects of resveratrol 
against adenine-mediated kidney disorders. The 
increased urine protein/creatinine ratio caused by 
adenine administration was also attenuated by 
treatment with resveratrol. Furthermore, our 
study demonstrated that rats administered 
adenine had higher serum levels of creatinine, 
BUN, and uric acid. Treatment of rats with 
resveratrol after administration of adenine 
inhibited the increases in creatinine, BUN, and 
uric acid levels in a dose-dependent manner.  
 
The results of this study showed that adenine 
administration caused changes in the renal 
tubules in the kidneys of rats; there was 
considerable swelling and expansion of the renal 
tubules. The level of dihydroxyadenine in the 
renal tubules of rats administered adenine was 
markedly higher than that of the normal control 
rats, and the renal tissues also had markedly 
increased levels of monocytes and inflammatory 
cells. However, resveratrol treatment inhibited 
the adenine-mediated increase in monocytes and 
inflammatory cells and prevented renal tubule 
swelling and expansion.  
 
Zhang et al 





Figure 4: Resveratrol treatment prevented adenine-induced pathological changes in the rat kidney. 
Rats administered adenine were treated with resveratrol at 10, 15, and 20 mg/kg doses or normal 





Resveratrol treatment prevents renal pathological 
changes induced by adenine administration in a 
CKD rat model by inhibiting FGF-23, parathyroid 
hormone, and phosphate. Thus, resveratrol may 
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